Over the last 12 months, AtriCure insiders reported no purchases and 13 sales totaling $3.9M across SEC Form 4 filings. 15% of those filings were made under pre-arranged 10b5-1 trading plans.
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | GROVES REGINA ED | ▼ Sale | 5,313 | $54.22 | $288K | -13.3% | — |
| Sep 8, 2026 | Privitera SalvatoreChief Technical Officer · O | ▼ Sale | 3,657 | $55 | $201K | -2.4% | plan |
| Sep 2, 2026 | Privitera SalvatoreChief Technical Officer · O | ▼ Sale | 7,763 | $52.5 | $408K | -4.9% | plan |
| Aug 24, 2026 | Dahlquist Karl S.Chief Legal Officer · O | ▼ Sale | 9,370 | $48.89 | $458K | -9.7% | — |
| Aug 5, 2026 | Prange KarenD | ▼ Sale | 3,564 | $38.8 | $138K | -13.5% | — |
| Aug 5, 2026 | Yuen MaggieD | ▼ Sale | 3,500 | $38.42 | $134K | -20% | — |
| Jul 29, 2026 | Noznesky Justin JChief Mktg & Strategy Officer · O | ▼ Sale | 6,182 | $38.8 | $240K | -5.8% | — |
| Jul 28, 2026 | Doraiswamy VinayakChief Scientific Officer · O | ▼ Sale | 6,000 | $38.88 | $233K | -6.5% | — |
| Jul 28, 2026 | WEHRWEIN SVEND | ▼ Sale | 25,000 | $37.84 | $946K | -38.2% | — |
| Mar 12, 2026 | Doraiswamy VinayakChief Scientific Officer · O | ▼ Sale | 5,000 | $29.83 | $149K | -4.9% | — |
| Nov 26, 2025 | Noznesky Justin JChief Mktg & Strategy Officer · O | ▼ Sale | 5,166 | $37.29 | $193K | -6.2% | — |
| Nov 25, 2025 | WEHRWEIN SVEND | ▼ Sale | 10,000 | $37.66 | $377K | -22.5% | 2 tranches |
| Nov 21, 2025 | Yuen MaggieD | ▼ Sale | 3,000 | $35.72 | $107K | -20.9% | — |
| Sep 12, 2025 | Noznesky Justin JChief Mktg & Strategy Officer · O | ▼ Sale | 3,000 | $36.3 | $109K | -3.4% | — |
| Aug 22, 2025 | WEHRWEIN SVEND | ▼ Sale | 5,000 | $37 | $185K | -12.7% | — |
| Aug 19, 2025 | WEHRWEIN SVEND | ▼ Sale | 5,000 | $36 | $180K | -12.7% | — |
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? AtriCure filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ATRC feed.